the aid library

LIST OPTIONS

Filter

5470

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Заболевание COVID-19 у детей и подростков Научная справка 29 сентября 2021 г.

World Health Organization WHO (2021) C_WHO

SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch... more

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended

World Health Organization (2015) C_WHO

The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of n... more

Download (342)

View PDF (565)

Weak surveillance and policy attention to cancer in global health: the example of Mozambique

Lorenzoni, C; Oliveras, Laura; Vilajeliu, A, et al. (2018) CC

Cancer is an emerging public health problem in sub-Saharan Africa due to population growth, ageing and westernisation of lifestyles. In this piece, we use data from Mozambique over a 50-year period to illustrate cancer epidemiological trends in low-income and middle-income countries to hypothesise ... more

Download (418)

View PDF (488)

Sexual Violence in Detention

International Committee of the Red Cross (ICRC) (2017) C1

We have long been working to prevent and end sexual violence in armed conflicts and to ensure that the countless victims – men, women, boys and girls – receive the help they need.
In this document, we examine sexual violence specifically in relation to people deprived of their liberty. We c... more

Download (479)

View PDF (754)

Guidelines on sanitation and health
recommended

World Health Organization WHO (2018) C_WHO

The new WHO Guidelines on Sanitation and Health summarize the evidence on the effectiveness of a range of sanitation interventions and provide a comprehensive framework for health-protecting sanitation, covering policy and governance measures, implementation of sanitation technologies, systems and b... more

Download (185)

View PDF (369)

Children under Siege: Pre-adolescence, PTSD, and Violent Conditions

Elisabeth Pitts Duke University (2013) C1

DIAGNOSING PTSD IN CHILDHOOD | The following literature review addresses the developmental and domain-specific consequences of previous and current diagnostic criteria for posttraumatic stress disorder (PTSD) in pre-adolescent children. PTSD was introduced in 1980 to capture extreme responses follow... more

Download (521)

View PDF (517)

Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017-2026

World Health Organization WHO (2018) C_WHO

The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives: protect at-risk populations; prevent international spread; and contain outbreaks rapidly.

Download (261)

View PDF (298)

The Power of Cities: Tackling Noncommunicable Diseases and Road Traffic Injuries

World Health Organization WHO (2019) C_WHO

The report is geared towards mayors, local government officials and city policy planners.It highlights key areas where city leaders can tackle the drivers of NCDs, including tobacco use, air pollution, poor diets and lack of exercise, and improve road safety. From anti-tobacco actions in Beijing a... more

Antibiotic resistance – undoing progress in maternal and child health

ReAct (2018) C2

Antibiotic resistant bacteria are spreading at an alarming rate and some bacterial infections may once again be untreatable. Antibiotic resistance (ABR), conservatively calculated, causes more than 500 000 deaths every year. This number is projected to rise dramatically if radical actions are not ta... more

Discrimination and Barriers Facing Women and Girls with Disabilities in Afghanistan

Human Rights Watch (2020) C2

Afghanistan has one of the largest populations per capita of persons with disabilities in the world. At least one in five Afghan households includes an adult or child with a serious physical, sensory, intellectual, or psychosocial disability. More than 40 years of war have left more than one million... more

What Are We Learning About Protecting Children in the Community? An inter-agency review of the evidence on community-based child protection mechanisms in humanitarian and development settings

Mike Wessells Save the Children (2008) CC

How to respond to, mitigate, and prevent risks to children’s protection and well-being is a profound, if unanswered, question. Practitioners agree that it is necessary to develop or strengthen protective factors at multiple levels, such as the family, community, and national levels.

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

External Link

Strengthening mental health responses to COVID-19 in the Americas: A health policy analysis and recommendations

A. Tausch; Oliveira e Souza, R.; Martinez Viciana, C.; et al. Pan American Health Organization (2021) CC

The COVID-19 pandemic is having a major impact on the mental health of populations in the Americas. Studies show high rates of depression and anxiety, among other psychological symptoms, particularly among women, young people, those with pre-existing mental health conditions, health workers, and p... more

Nigeria: Demographic Health Survey 2018

The DHS Program ICF USAID (2019) C2

The 2018 NDHS is a national sample survey that provides up-to-date information on demographic and health indicators. The sample was selected using a stratified, two-stage cluster design, with enumeration areas (EAs) as the sampling units for the first stage. The second stage was a complete listing o... more

External Link

The social context of schistosomiasis and its control

Brunn, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO (2008) C_WHO

Schistosomiasis is widely recognized as a disease that is socially determined. An understanding of the social and behavioural factors linked to disease transmission and control should play a vital role in designing policies and strategies for schistosomiasis prevention and control. To this must be a... more

External Link

The social context of schistosomiasis and its control: an introduction and annotated bibliography

Bruun, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO; Institutional Repository for Information Sharing iris (2008) C_WHO

Epidemiology of human African trypanosomiasis

Franco J, Simarro P, Diarra A, Jannin J (2014) CC

The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environment. Related to these interactions, the disease is confined in spatially limited areas called “foci�... more

Download (265)

View PDF (338)

Red and processed meat in the context of health and the environment: many shades of red and green: information brief

World Health Organisation (WHO) (2023) C_WHO

There is growing international consensus that food systems transformation is important to address the challenges of malnutrition in all its forms, the burden of noncommunicable diseases (NCDs), environmental sustainability, increasing inequality and ensuring the welfare of workers and animals. In li... more

Pharmacological Primary Prevention of Diabetes Mellitus Type II: A Narrative Review

Naveed, A.; Farrukh, L.; Khawar Sana, M.; et al. National Library of Medicine (2020) CC2

The evolving epidemic of type 2 diabetes mellitus has challenged health-care professionals. It stands among the leading causes of mortality in the present world. It warrants new and versatile approaches to improve mortality and the associated huge quality-adjusted life years lost to it once diagnose... more

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection recommended

Guidelines on sanitation and health recommended

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended

Guidelines on sanitation and health
recommended